Home › Calculator › LGNYZ Dividend Calculator 2026
LGNYZ Dividend DRIP Calculator 2026
8.95% YieldHealthcareLigand Pharmaceuticals Incorporated · OTC
Price: $0.04 · Annual div: $0.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When LGNYZ pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your LGNYZ snowball 📈
$10,000 in LGNYZ → $91.9K in 10 years · $105.61/month
About Ligand Pharmaceuticals Incorporated (LGNYZ) — Dividend Analysis 2026
Ligand Pharmaceuticals Incorporated functions as a global biopharmaceutical entity, concentrating on the advancement and licensing of pharmaceutical assets. Its diverse portfolio includes commercial products targeting a wide array of serious health conditions. Key therapeutic offerings comprise Kyprolis and Evomela for the treatment of multiple myeloma, alongside Rylaze, an asparaginase formulation designed for both adult and pediatric patients battling acute lymphoblastic leukemia or lymphoblastic lymphoma. The company also provides Filspari, a dual endothelin and angiotensin II receptor antagonist, currently being developed for specific rare kidney diseases and as a non-immunosuppressive treatment for immunoglobulin A nephropathy. Further extending its reach, Ligand's portfolio features a teriparatide injection product for osteoporosis management. In the vaccine space, Vaxneuvance aims to prevent invasive disease caused by Streptococcus pneumoniae serotypes, while Pneumosil offers a pneumococcal conjugate vaccine primarily for children. A notable advancement is TZIELD, a CD3-directed antibody indicated to postpone the progression to Stage 3 type 1 diabetes in adults and children aged eight years and older who have Stage 2 T1D. Many of Ligand's solutions leverage its proprietary Captisol technology, enhancing drug formulations. Examples include Nexterone (a Captisol-enabled amiodarone), Zulresso (a Captisol-enabled brexanolone for postpartum depression), and Veklury, an antiviral treatment for moderate or severe COVID-19. The Captisol platform also supports Noxafil-IV, an IV formulation of posaconazole. Additional products in their repertoire address various indications such as post-menopausal symptoms (Duavee), autoimmune diseases (Exemptia), breast cancer (Vivitra), and other conditions through Bryxta and Zybev. Beyond its licensed therapies, Ligand also directly markets its Captisol materials. The company fosters strategic alliances, licenses, and business relationships with prominent pharmaceutical firms, including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Ligand Pharmaceuticals Incorporated, founded in 1987, maintains its headquarters in Jupiter, Florida.
Compare LGNYZ with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full LGNYZ DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open LGNYZ position with:
🌍 LGNYZ Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold LGNYZ.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 8.95% | 6.15% | $895 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 7.61% | 4.81% | $761 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 7.16% | 4.36% | $716 / yr |
| 🇬🇧 UK ISA | 0% | 8.95% | 6.15% | $895 / yr |
| 🇬🇧 UK Taxable | 8.75% | 8.17% | 5.37% | $817 / yr |
| 🇨🇦 TFSA | 0% | 8.95% | 6.15% | $895 / yr |
| 🇨🇦 CA Taxable | 25% | 6.71% | 3.91% | $671 / yr |
| 🇦🇺 Super (pension) | 15% | 7.61% | 4.81% | $761 / yr |
| 🇦🇺 AU Taxable | 30% | 6.26% | 3.46% | $626 / yr |
| 🇩🇪 DE Taxable | 26.375% | 6.59% | 3.79% | $659 / yr |
| 🇫🇷 FR Taxable | 30% | 6.26% | 3.46% | $626 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 LGNYZ Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 LGNYZ Dividend Payment Schedule
LGNYZ pays quarterly — 4 times per year. Next ex-div: TBD.
📊 LGNYZ vs Healthcare Benchmarks
How LGNYZ compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for LGNYZ sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ LGNYZ Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| F-InKind | 2024-01-02 | 2,917 | $72.31 | $210.9K | ||
| J-Other | 2023-12-29 | 179 | $60.71 | $10.9K | ||
| F-InKind | 2023-12-05 | 1,269 | $59.61 | $75.6K | ||
| F-InKind | 2023-12-05 | 1,984 | $59.61 | $118.3K | ||
| F-InKind | 2023-10-01 | 346 | $59.92 | $20.7K | ||
| A-Award | 2023-09-22 | 11,345 | $59.08 | $670.3K | ||
| A-Award | 2023-09-22 | 2,285 | — | — | ||
| Buy | 2023-09-22 | 4,000 | $59.38 | $237.5K | ||
| F-InKind | 2023-08-10 | 897 | $68.73 | $61.7K | ||
| J-Other | 2023-06-30 | 376 | $56.78 | $21.3K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the LGNYZ dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Ligand Pharmaceuticals Incorporated (LGNYZ) is currently trading at $0.04, 37% below its 52-week high. The current dividend yield is 8.95% based on an annual payout of $0.00 per share.
LGNYZ (Ligand Pharmaceuticals Incorporated) — 8.95% Dividend Yield Analysis
Ligand Pharmaceuticals Incorporated (LGNYZ) is a healthcare stock currently trading at $0.04 with a dividend yield of 8.95%. The company pays an annual dividend of $0.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (8.95%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.